Literature DB >> 2190321

Current status of iron chelation therapy with deferoxamine.

A Cohen1.   

Abstract

Long-term chelation therapy with deferoxamine is an effective and generally safe method for removing excessive iron, preventing iron-induced organ damage and improving survival of patients with transfusion-dependent disorders. The current treatment of iron overload is an important standard against which new forms of therapy, such as oral chelators, should be measured to ensure that their risks and benefits compare favorably with deferoxamine. Until new treatments are available, continuing studies of deferoxamine will help to define its long-term efficacy and toxicity for patients with thalassemia major and other hematologic disorders.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190321

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  4 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice.

Authors:  J Lan; D H Jiang
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Frequency of sensory neural hearing loss in major Beta-thalassemias in southern iran.

Authors:  Abolhassan Faramarzi; Mehran Karimi; Seyed-Taghi Heydari; Mahmoud Shishegar; Masoud Kaviani
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

4.  Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review.

Authors:  J Caro; Krista F Huybrechts; Traci C Green
Journal:  BMC Blood Disord       Date:  2002-11-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.